Prophylactic Ureteral Stenting Linked to Upper Tract Urothelial Carcinoma
In current urological practice, clinicians decide whether to place a ureteral stent or nephrostomy, but evidence-based treatment guidance is needed.
Bladder Cancer News
BLADDER CANCER ADVISOR
Bladder Cancer News
Trodelvy Gets Accelerated Approval for Urothelial Cancer
The accelerated approval was based on data from the multicenter, open-label, phase 2 TROPHY study.
Seminal Vesicle-Sparing in Radical Cystectomy Shown to Improve Outcomes
Seminal vesicle-sparing radical cystectomy improved functional results over a median of 64 months without compromising oncologic outcomes, according to investigators.
Oncologic Outcomes, Costs of High-Risk NMIBC Need to Improve
High-risk NMIBC progression more than doubled healthcare costs over 5 years compared with no progression, a study found.
Tecentriq Indication for Prior-Platinum Treated Bladder Cancer Withdrawn
In 2016, the FDA granted accelerated approval to Tecentriq for prior-platinum treated metastatic urothelial carcinoma based on tumor response rate and duration of response.
Model Proposed to Guide Use of Adjuvant Radiation Therapy for MIBC
Investigators found that the odds of locoregional recurrence of muscle-invasive bladder cancer following radical cystectomy depend on disease risk category.
Algorithm Proposed to Expand Cisplatin Eligibility for MIBC
A new algorithm developed by Canadian investigators aims to address underuse of cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Imfinzi Indication for Urothelial Carcinoma Withdrawn
Under the accelerated approval program, if a confirmatory trial does not show clinical benefit, the FDA can take steps to remove the drug or indication.
AstraZeneca Voluntarily Withdraws Imfinzi Indication in Locally Advanced or Metastatic Bladder Cancer
AstraZeneca has voluntarily withdrawn durvalumab’s (Imfinzi’s) indication for adults with locally advanced or metastatic bladder cancer.
COVID-19 Adversely Affecting Patients With Genitourinary Cancers
In an online survey, 17.2% of patients with genitourinary cancers reported they delayed or avoided seeking medical care because of the COVID-19 pandemic.
Vicineum gets Priority Review for High-Risk, BCG-Unresponsive NMIBC
Vicineum has been awarded a priority review for patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Tumor Mutational Burden, Immune-Related Adverse Events in Metastatic Urothelial Cancer
Researchers analyzed data from patients with metastatic urothelial cancer to determine whether tumor mutation burden was associated with immune-related AEs among patients treated with immune checkpoint inhibitors.
Demographic Factors With Stage at Diagnosis and Use of Treatment in Bladder Cancer
Researchers sought to identify social disparities in diagnosis and treatment among patients with bladder cancer.
Bladder Pressure May Influence Intravesical Drug Delivery
Using porcine bladders, researchers investigated whether bladder pressure affects the extent to which gemcitabine penetrates the bladder wall with this treatment modality.
Sexual Orientation May Influence Choice to Pursue Screening for ‘Gender-Specific’ Cancers
Investigators studied whether sexual orientation affects screening for prevalent gender-specific cancers including prostate, breast, and cervical cancer.
Race Reporting in GU Cancers Indicates Relative Overrepresentation of White Individuals
Lythgoe et al studied patterns of race reporting in genitourinary (GU) cancer trials.
Radiation Therapy Increases Survival in Metastatic Urothelial Carcinoma
Patients with metastatic urothelial carcinoma have significantly longer overall survival when treated with a combination of radiotherapy and chemotherapy compared with chemotherapy alone, a study found.
Study Identifies Risk Factors for Urethral Recurrence After Radical Cystectomy
Study findings support surveillance for urethral recurrence after radical cystectomy.
Primary EV-301 Results Confirm Enfortumab Vedotin’s Superiority Over Chemotherapy in Advanced Urothelial Carcinoma
Powles et al present the primary results from the phase 3 EV-301 trial in advanced urothelial carcinoma.
Adjuvant Nivolumab Improves DFS in MIUC After Radical Surgery
CheckMate 274 investigators compared adjuvant nivolumab with placebo (PBO) in patients with MIUC who received cisplatin prior to radical surgery.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
